New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
The EasySep™ Dead Cell Removal (Annexin V) kit is designed to deplete apoptotic (Annexin V+) cells from cell culture or tissue preparations by immunomagnetic negative selection. Unwanted cells are labeled with Annexin V, antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Labeled cells are separated using an EasySep™ magnet without the use of columns. Desired cells are simply poured off into a new tube. Annexin V binds phosphatidylserine on the outer leaflet of the cell membrane during apoptosis.
• Fast and easy-to-use
• No columns required
• Compatible across EasySep™, "The Big Easy", and EasyEights™ platforms
EasySep™ Dead Cell Removal (Annexin V) Kit (Catalog #17899)
EasySep™ Dead Cell Removal (Annexin V) Cocktail, 0.5 mL
EasySep ™ Biotin Selection Cocktail, 1 mL
EasySep™ Dextran RapidSpheres™ 50103, 1 mL
• EasySep™ Magnet (Catalog #18000), or
• “The Big Easy” EasySep™ Magnet (Catalog #18001), or
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
Depletion of Dead Cells from Primary Tissue in 6 Minutes
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Starting with human polymorphonuclear cells (PMNCs) cultured overnight, the live cell content (AnnexinV-/PI-) of the enriched fraction is typically 69.7± 12.5% (mean ± SD using the purple EasySep™ Magnet). In the above example, the percentages of live cells in the start and final enriched fractions are 12.8% and 74.9%, respectively.
Starting with 24- to 48-hour-old mouse splenocytes, the live cell content of the enriched fraction is typically 79.8 ± 11.4% (mean ± SD using the purple EasySep™ Magnet). In the above example, the percentages of live cells in the start and final enriched fractions are 78.1% and 93.4%, respectively.
Cancer research 2020 sep
A Pygopus 2-Histone Interaction Is Critical for Cancer Cell Dedifferentiation and Progression in Malignant Breast Cancer.
M. Saxena et al.
Pygopus 2 (Pygo2) is a coactivator of Wnt/$\beta$-catenin signaling that can bind bi- or trimethylated lysine 4 of histone-3 (H3K4me2/3) and participate in chromatin reading and writing. It remains unknown whether the Pygo2-H3K4me2/3 association has a functional relevance in breast cancer progression in vivo. To investigate the functional relevance of histone-binding activity of Pygo2 in malignant progression of breast cancer, we generated a knock-in mouse model where binding of Pygo2 to H3K4me2/3 was rendered ineffective. Loss of Pygo2-histone interaction resulted in smaller, differentiated, and less metastatic tumors, due, in part, to decreased canonical Wnt/$\beta$-catenin signaling. RNA- and ATAC-sequencing analyses of tumor-derived cell lines revealed downregulation of TGF$\beta$ signaling and upregulation of differentiation pathways such as PDGFR signaling. Increased differentiation correlated with a luminal cell fate that could be reversed by inhibition of PDGFR activity. Mechanistically, the Pygo2-histone interaction potentiated Wnt/$\beta$-catenin signaling, in part, by repressing the expression of Wnt signaling antagonists. Furthermore, Pygo2 and $\beta$-catenin regulated the expression of miR-29 family members, which, in turn, repressed PDGFR expression to promote dedifferentiation of wild-type Pygo2 mammary epithelial tumor cells. Collectively, these results demonstrate that the histone binding function of Pygo2 is important for driving dedifferentiation and malignancy of breast tumors, and loss of this binding activates various differentiation pathways that attenuate primary tumor growth and metastasis formation. Interfering with the Pygo2-H3K4me2/3 interaction may therefore serve as an attractive therapeutic target for metastatic breast cancer. SIGNIFICANCE: Pygo2 represents a potential therapeutic target in metastatic breast cancer, as its histone-binding capability promotes $\beta$-catenin-mediated Wnt signaling and transcriptional control in breast cancer cell dedifferentiation, EMT, and metastasis.
Nature microbiology 2020 jun
Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis A virus infection.
M. I. Costafreda et al.
Cell-to-cell communication by exosomes controls normal and pathogenic processes1,2. Viruses can spread in exosomes and thereby avoid immune recognition3. While biogenesis, binding and uptake of exosomes are well characterized4,5, delivery of exosome cargo into the cytoplasm is poorly understood3. We report that the phosphatidylserine receptor HAVCR1 (refs. 6,7) and the cholesterol transporter NPC1 (ref. 8) participate in cargo delivery from exosomes of hepatitis A virus (HAV)-infected cells (exo-HAV) by clathrin-mediated endocytosis. Using CRISPR-Cas9 knockout technology, we show that these two lipid receptors, which interact in the late endosome9, are necessary for the membrane fusion and delivery of RNA from exo-HAV into the cytoplasm. The HAVCR1-NPC1 pathway, which Ebola virus exploits to infect cells9, mediates HAV infection by exo-HAV, which indicates that viral infection via this exosome mimicry mechanism does not require an envelope glycoprotein. The capsid-free viral RNA in the exosome lumen, but not the endosomal uncoating of HAV particles contained in the exosomes, is mainly responsible for exo-HAV infectivity as assessed by methylene blue inactivation of non-encapsidated RNA. In contrast to exo-HAV, infectivity of HAV particles is pH-independent and requires HAVCR1 or another as yet unidentified receptor(s) but not NPC1. Our findings show that envelope-glycoprotein-independent fusion mechanisms are shared by exosomes and viruses, and call for a reassessment of the role of envelope glycoproteins in infection.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Contact STEMCELL Technologies